FR3061019B1 - Procede et systeme pour conditionner des composes lipidiques pour alicaments ou medicaments. - Google Patents

Procede et systeme pour conditionner des composes lipidiques pour alicaments ou medicaments. Download PDF

Info

Publication number
FR3061019B1
FR3061019B1 FR1663398A FR1663398A FR3061019B1 FR 3061019 B1 FR3061019 B1 FR 3061019B1 FR 1663398 A FR1663398 A FR 1663398A FR 1663398 A FR1663398 A FR 1663398A FR 3061019 B1 FR3061019 B1 FR 3061019B1
Authority
FR
France
Prior art keywords
lipid compound
capsule
alicaments
medicaments
conditioning
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1663398A
Other languages
English (en)
Other versions
FR3061019A1 (fr
Inventor
Bernard Jacques Kurdyk
Jean-Pierre Lablanchy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Belles Feuilles
Cabinet Du Docteur Bernard Kurdyk
Original Assignee
Belles Feuilles
Cabinet Du Docteur Bernard Kurdyk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Belles Feuilles, Cabinet Du Docteur Bernard Kurdyk filed Critical Belles Feuilles
Priority to FR1663398A priority Critical patent/FR3061019B1/fr
Priority to EP17826513.8A priority patent/EP3558274A1/fr
Priority to US16/473,175 priority patent/US20190314287A1/en
Priority to JP2019555720A priority patent/JP2020509781A/ja
Priority to PCT/EP2017/084259 priority patent/WO2018122128A1/fr
Publication of FR3061019A1 publication Critical patent/FR3061019A1/fr
Application granted granted Critical
Publication of FR3061019B1 publication Critical patent/FR3061019B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/30—Encapsulation of particles, e.g. foodstuff additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A61J3/071—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use into the form of telescopically engaged two-piece capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Fodder In General (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Procédé pour conditionner un composé lipidique destiné à être ingéré par un corps humain ou animal, comprenant les étapes suivantes : - remplissage (I) d'une première partie d'une capsule préfabriquée, préalablement ouverte en deux parties, avec un volume prédéterminé d'un composé lipidique ; - insertion (II) d'un absorbant lipophile alimentaire dans le composé lipidique (4) au sein de cette première partie, de façon à réaliser, à l'issue de l'absorption du composé lipidique, un cœur sous la forme d'un mélange pâteux procurant une vitesse de dissolution prédéterminée, - fermeture (III) de la capsule en plaçant la seconde partie sur la première partie contenant le cœur ; et - enrobage de la capsule ainsi refermée, par un polymère, de façon à permettre une libération ultérieure du composé lipidique en un lieu de libération prédéterminé au sein dudit corps humain ou animal. Utilisation dans le domaine de l'industrie agro-alimentaire et pharmaceutique.
FR1663398A 2016-12-26 2016-12-26 Procede et systeme pour conditionner des composes lipidiques pour alicaments ou medicaments. Expired - Fee Related FR3061019B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR1663398A FR3061019B1 (fr) 2016-12-26 2016-12-26 Procede et systeme pour conditionner des composes lipidiques pour alicaments ou medicaments.
EP17826513.8A EP3558274A1 (fr) 2016-12-26 2017-12-21 Procede et systeme pour conditionner des composes lipidiques pour alicaments ou medicaments
US16/473,175 US20190314287A1 (en) 2016-12-26 2017-12-21 Method and System for Conditioning Lipid Compounds for Medicinal Foods and Medicinal Products
JP2019555720A JP2020509781A (ja) 2016-12-26 2017-12-21 薬用食品および医薬品のための脂質化合物を包装する方法およびシステム
PCT/EP2017/084259 WO2018122128A1 (fr) 2016-12-26 2017-12-21 Procede et systeme pour conditionner des composes lipidiques pour alicaments ou medicaments

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1663398 2016-12-26
FR1663398A FR3061019B1 (fr) 2016-12-26 2016-12-26 Procede et systeme pour conditionner des composes lipidiques pour alicaments ou medicaments.

Publications (2)

Publication Number Publication Date
FR3061019A1 FR3061019A1 (fr) 2018-06-29
FR3061019B1 true FR3061019B1 (fr) 2019-05-24

Family

ID=58669904

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1663398A Expired - Fee Related FR3061019B1 (fr) 2016-12-26 2016-12-26 Procede et systeme pour conditionner des composes lipidiques pour alicaments ou medicaments.

Country Status (5)

Country Link
US (1) US20190314287A1 (fr)
EP (1) EP3558274A1 (fr)
JP (1) JP2020509781A (fr)
FR (1) FR3061019B1 (fr)
WO (1) WO2018122128A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020161398A1 (fr) 2019-02-07 2020-08-13 Belles Feuilles Composition et gélules la contenant notamment pour réduire ou éliminer un biofilm
US20220008289A1 (en) * 2020-07-09 2022-01-13 Tiffany Rowan Pill capsule holding device for improved handling of sprinkle, powder, and granules medication

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9509764D0 (en) * 1995-05-15 1995-07-05 Tillotts Pharma Ag Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids

Also Published As

Publication number Publication date
FR3061019A1 (fr) 2018-06-29
JP2020509781A (ja) 2020-04-02
EP3558274A1 (fr) 2019-10-30
US20190314287A1 (en) 2019-10-17
WO2018122128A1 (fr) 2018-07-05

Similar Documents

Publication Publication Date Title
CL2017000829A1 (es) Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un agente tamponante, y citrato; uso de dicha formulación para tratar enfermedad inflamatoria del intestino.
WO2016172396A3 (fr) Seringue de distribution séquentielle à chambres multiples
BRPI0707612B8 (pt) vaso lacrado e formulações líquidas contidas no mesmo
FR3061019B1 (fr) Procede et systeme pour conditionner des composes lipidiques pour alicaments ou medicaments.
JP2019530706A5 (fr)
FR3061151B1 (fr) Procede et systeme pour conditionner un compose lipidique en doses, capsules de compose lipidique ainsi obtenues et applications de ces capsules.
CN202061093U (zh) 一种对称式介入液体混合装置
PH12018501693A1 (en) Perfusion system
MA38912A1 (fr) Formulations pharmaceutiques effervescentes pauvres en sodium
Crump et al. A randomized phase III study of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin as salvage chemotherapy followed by posttransplantation rituximab maintenance therapy versus observation for treatment of aggressive B-Cell and T-Cell non-Hodgkin's lymphoma
Sharif et al. Corrigendum to'The role of dietary sodium in autoimmune diseases: The salty truth'[AUTREV 17-11 (2018) 1069-1073]
Sanai Propylthiouracil/thiamazole
Tabah et al. Are new gentamicin dosing guidelines suitable for achieving target concentrations in patients with sepsis and septic shock?
Vlahovic et al. Abstract B58: Phase I study of the IGF-1R antibody ganitumab (AMG 479) in combination with everolimus in patients with advanced solid tumors.
Tammela et al. Safety and efficacy of ODM-201 in chemotherapy and CYP17-inhibitor naïve patients: analysis of data from the ARADES and the ARAFOR trials
Kumar Osmotic nephropathy and acute renal failure in an elderly patient: case report
WO2014178081A3 (fr) Pièges moléculaires pour certaines substances indésirables
Fechtenbaum Toxidermia: case report
TH113758A (th) องค์ประกอบเชิงเภสัชกรรมสำหรับการให้ยาโดยการรับประทาน
MA37845B2 (fr) Compositions liquides orales pédiatriques contenant du nepadutant
Katsuma Acute interstitial nephritis along with granulomatous hepatitis: case report
Cittadini Misoprostol overdose
Redondo Hypertension and proteinuria: case report
Srinivasan Paracetamol/acetylcysteine overdose
Miro DRESS syndrome: case report

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20180629

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

ST Notification of lapse

Effective date: 20220808